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Changes in thebalancebetweenglutamate (Glu) release anduptakemay stimulate synaptic reorganizationandeven synapse loss. In the caseof
neurodegeneration, amismatch between astroglial Glu uptake and presynaptic Glu release could be detected if both parameters were assessed
independentlyandatasingle-synapse level.Thishasnowbecomepossibledue toanewimagingassaywith thegenetically encodedultrafastGlu
sensoriGluu.Wereportfindingsfromindividualcorticostriatalsynapsesinacuteslicespreparedfrommiceofeithersexthatwere1yearofage.
Contrastingpatternsof short-termplasticityandasizecriterion identified twoclassesof terminals,presumablycorresponding to thepreviously
defined IT (intratelencephalic) and PT (pyramidal tract) synapses. The latter exhibited a higher degree of frequency potentiation/residual Glu
accumulation and were selected for our first iGluu single-synapse study in Q175mice, a model of Huntington’s disease (HD). In HDmice, the
decay time constant of the perisynaptic Glu concentration (TauD), as an indicator of uptake, and the peak iGluu amplitude, as an indicator of
release, were prolonged and reduced, respectively. Treatment ofWT preparations with the astrocytic Glu uptake blocker TFB-TBOA (100 nM)
mimicked the TauD changes in homozygotes. Considering the largest TauD values encountered inWT,40% of PT synapses tested
in Q175 heterozygotes can be classified as dysfunctional. Moreover, HD but not WT synapses exhibited a positive correlation between
TauD and the peak amplitude of iGluu. Finally, EAAT2 (excitatory amino acid transport protein 2) immunoreactivitywas reduced next to
corticostriatal terminals. Thus, astrocytic Glu transport remains a promising target for therapeutic intervention.
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Introduction
A low level of extracellular glutamate concentration [Glu] is an
important prerequisite for high spatial and temporal discrimina-
tion of afferent signals. Electrogenic transport of Glu from the
environment of active synaptic terminals into astroglial cells
secures resting [Glu] levels of 100 nm (Bergles et al., 1999;
Marcaggi and Attwell, 2004; Tzingounis andWadiche, 2007; Ne-
dergaard and Verkhratsky, 2012; Papouin et al., 2017; Rose et al.,
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Significance Statement
Alterations in astrocytic Glu uptake can play a role in synaptic plasticity and neurodegeneration. Until now, the sensitivity of
synaptic responses to pharmacological transport block and the resulting activation of NMDA receptors were regarded as reliable
evidence for a mismatch between synaptic uptake and release. But the latter parameters are interdependent. Using a new geneti-
cally encoded sensor to monitor extracellular glutamate concentration ([Glu]) at individual corticostriatal synapses, we can now
quantify the timeconstantofperisynaptic [Glu]decay (as an indicatorofuptake) and themaximal [Glu] elevationnext to theactive
zone (as an indicator of Glu release). The results provide a positive answer to the hitherto unresolved question of whether
neurodegeneration (e.g., Huntington’s disease) associates with a glutamate uptake deficit at tripartite excitatory synapses.
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2018). Compared with other synaptically enriched proteins, in-
cluding the AMPA receptors, excitatory amino acid transport
proteins are very abundant (Lehre and Danbolt, 1998; Marcaggi
and Attwell, 2004; Cahoy et al., 2008), forming clusters on the
perisynaptic astroglial processes (PAPs) next to the sites of trans-
mitter release (Lehre and Danbolt, 1998; Melone et al., 2011).
However, the proximity between the sites of synaptic Glu release
and astrocytic uptake could vary according to the type of synapse
or the functional state of the involved cells (Octeau et al., 2018).
Insufficient expression/activity of Excitatory Amino Acid
Transporter 2 (EAAT2) is considered among the mechanisms
promoting excitotoxic damage and neurodegeneration (Pekny et
al., 2016; Verkhratsky et al., 2016). As for Huntington’s disease
(HD), there is full agreement that the transcription of the
EAAT2-encoding gene SLC1A2 and tissue uptake of radiolabeled
EAAT2 substrates are reduced in comparison with healthy con-
trols (Lievens et al., 2001; Behrens et al., 2002; Shin et al., 2005;
Miller et al., 2008; Bradford et al., 2009; Faideau et al., 2010;
Huang et al., 2010; Menalled et al., 2012; Grewer et al., 2014;
Meunier et al., 2016). Records from striatal astrocytes (Dvorzhak
et al., 2016) suggested a 20–30%decrease in the glutamate uptake
activity in two mouse models of HD, R6/2 and Q175. Yet some
caution is needed as it has remained unclear whether or not the well
documented reduction of astrocytic Glu transport is to be regarded
as a primary cause of synapse dysfunction/loss, or merely as an epi-
phenomenon reflecting glial adjustment to the massive pruning of
glutamatergic terminals for other yet unknown reasons (Deng et al.,
2013;Rotheetal., 2015).As synapsedegeneration is likely toprogress
in a rather asynchronous manner resulting in a coexistence of dys-
functional and more or less healthy terminals, a satisfying answer
regarding the adequate performance of astrocytic glutamate uptake
in HD can be obtained only at the single-synapse level and under
consideration of the individual uptake/release relationships (Bar-
bour, 2001; Nahir and Jahr, 2013; Jensen et al., 2017; Reynolds et al.,
2019).
The striatum as the most affected brain structure in HD
(Khakh et al., 2017) is well suited for selective activation of glu-
tamatergic synapses since it lacks intrinsic glutamatergic neu-
rons. Glutamatergic afferents originate in the medial thalamus
and the cerebral cortex (for review, see Reiner and Deng, 2018).
Corticostriatal connections are formed by at least two distinct pop-
ulations of pyramidal neurons, localized in layers 2/3 and 5.
The axons originating in layer 2/3 establish bilateral intratelen-
cephalic (IT) connections, while layer 5 axons enter the pyramidal
tract (PT) and lack telencephalic collaterals to the contralateral
side. Elegant electrophysiology studies (Kincaid et al., 1998) and
electron microscopy studies (Reiner et al., 2010) discovered a
number of differences between PT and IT afferents and their
synaptic varicosities. In view of this diversity, one could expect
some type-dependent differences in the release characteristics
and, accordingly, differential sensitivity to factors that may
cause an uptake/release imbalance.
Herewe report the results of the first single-synapse experiments in
striatal slicesofadultmiceperformedwiththeultrafastGlusensor iGluu
(Helassa et al., 2018).Wehave addressed the following three questions.
(1) How does activation frequency affect the Glu release and uptake at
corticostriatal terminals? (2) Does HD produce an uptake/releasemis-
match? (3) If so, could the indicatorsofuptakeand/or releasebeused to
identify dysfunctional synapses?
Materials andMethods
Animals. The work described here has been performed in accordance
with EU Directive 2010/63/EU for animal experiments and was regis-
tered at the Berlin Office of Health Protection and Technical Safety
(G0233/14 and G0218/17). Z-Q175-KI mice were obtained from CHDI
(Cure Huntington’s Disease Initiative; stock #027410, The Jackson Lab-
oratory). The number of CAG repeats ranged from 182 to 193. The
recordings were performed in animals of either sex at 51–76weeks of age.
Plasmids.pAAV-CaMKIIa-ChR2(H134R)-EYFP (catalog #26969, Ad-
dgene) and pAAV-CaMKIIa-hChR2(E123T/T159C)-EYFP (catalog
#35511, Addgene) were gifts fromKarl Deisseroth (StanfordUniversity).
To create pAAV-CaMKIIa-iGluu (catalog #75443, Addgene), the iGluu
gene was amplified by PCR from pCI-syn-iGluu (catalog #106122, Add-
gene) using Phusion polymerase (forward, 5-CATCAGGATCCAT
GGAGACAGACACACTCC-3; reverse, 5-GTATGGAATTCCTAAC
GTGGCTTCTTCTGCC-3) and cloned into pAAV-CaMKIIa-hChR2
(H134R)-EYFP by restriction ligation using BamHI/EcoRI restriction
enzymes (New England BioLabs) and T4 DNA ligase (New England
BioLabs). AAV9-CaMKIIa.iGluu.WPRE-hGH and AAV9-CaMKIIa.
hChR2(E123T/T159C)-EYFP.hGH were packaged at the Penn Vector
Core of the University of Pennsylvania (Philadelphia, PA).
Drugs and antibodies. All substances were obtained from Sigma-Al-
drich/Merck, except for tetrodotoxin (TTX; Abcam) and TFB-TBOA
(Tocris Bioscience). The primary antibodies included those to vGluT1
(1:1000; guinea pig; catalog #135304, Synaptic Systems) and EAAT2
(1:2000; rabbit; catalog #ab41621, Abcam). Secondary antibodies
against guinea pig and rabbit, were conjugated to Alexa Fluor 488
(catalog #A-11073) or 555 (catalog #A-21429), obtained from
Thermo Fisher Scientific.
Injections and brain slice preparation.The animals were anesthetized by
intraperitoneal injection of a mixture containing 87.5 mg/kg ketamine
and 12.5mg/kg xylazine before receiving four 1l intracortical injections
of AAV9-CaMKII.iGluu.WPRE-hGH [7.34 10
13 genome copies (gc)/
ml] or one 1 l intracortical injection of AAV9-CaMKIIa.hChR2
(E123T/T159C)-EYFP.hGH (6.28  1012 gc/ml) at the following
coordinates with respect to bregma (mm): anterior 1.5, lateral 1.56, 1.8,
2.04, 2.28 and ventral 1.7. Three to six weeks later, the animals were
anesthetizedwith isoflurane, transcardially perfusedwith cooled, aerated
saline containing the following (in mM): N-methylglucamine chloride
92, KCl 2.5, NaH2PO4 1.25, NaHCO3 25, glucose 20, CaCl2 0.5, MgCl2
10, sodium pyruvate 3, and sodium ascorbate 5, at pH 7.35 and 303
mOsm/L. After decapitation and removal of the brains, parasagittal (10°
off) sections (300 m) containing the striatum were prepared as previ-
ously described (Dvorzhak et al., 2016). The slices were kept in artificial
CSF (ACSF) containing the following (in mM): NaCl 125, KCl 3,
NaH2PO4 1.25, NaHCO3 25, CaCl2 2, MgCl2 1, and glucose 10, at pH 7.3
and 303 mOsm/L. This was supplemented with the following (in mM):
sodiumpyruvate 0.5, sodium ascorbate 2.8, and glutathione 0.005. These
perfusion and recovery solutions preserved the astrocytes better than
physiological ACSF, or sucrose-containing or choline-containing solu-
tions, the criteria being restingmembrane potential at break-in (WT, less
than or equal to 85 mV). Q175 homozygotes (HOMs) were also in-
jected with ceftriaxone (CEF; 5 consecutive days before testing, 200 mg/
kg, i.p.) or the respective control solution (physiological saline).
Quantification of synaptic [Glu] elevations with iGluu. The biophysical
characteristics of the new ultrafast Glu sensor (iGluu) have already been
described (Helassa et al., 2018). Briefly, responses to saturating Glu con-
centration (10 mM) were recorded in transduced HEK293T cells. An
iGluu off rate of 2.1 ms was determined using recombinant purified
protein and stopped flow fluorimetry. For the imaging of synaptically
released Glu, slices were submerged into a perfusion chamber with a
constant flow of oxygenated ACSF at a rate of 1–2 ml/min. Temperature
during the recordings was maintained at 26–27°C. In nonstimulated
acute slices frommice1 year old, corticostriatal varicosities were visu-
alized in the dorsal striatum using a Zeiss Plan-Apochromat 63/nu-
merical aperture (NA) 1.0 water-immersion objective and brief (180ms)
discontinuous exposure to a 473 nm laser beam focused to a circular area
of 4.5 m in diameter centered on a presynaptic varicosity. The dis-
tance to the nearest other fluorescent varicosity was typically 3–5 m.
The size of nonstimulated boutons was derived from the area of suprath-
reshold pixels, the threshold being defined as the mean region of interest
(ROI) intensity plus 3 SDs. For the evaluation of evoked responses, the
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iGluu fluorescence was acquired at a frequency of 2.5 kHz from a rectan-
gular ROI of 4  4 m (20  20 pixels, binning 2) using a scientific
complementary metal-oxide-semiconductor (sCMOS) camera (Andor
Zyla4.2 PLUS,Oxford Instruments) attached to a Zeiss wide-fieldmicro-
scope (AxioObserver). In-house written software routines controlled the
laser, camera, and electrical stimulation of the axon/bouton. Each pixel
of the ROI was evaluated separately for the construction of time- and
space-dependent [Glu] profiles after release. The iGluu intensity values
were expressed as suprathreshold pixel fluorescenceF in the percentage
of the mean baseline fluorescence derived from the data points acquired
during a 50ms period before stimulation. The stimulus-induced changes
of suprathresholdF/F (change at the peak of averaged transient derived
from all suprathreshold pixels) in time or space are referred to as “iGluu
transients” or, simply, as “transients.”
For the quantification of iGluu at single synapses, we defined the fol-
lowing key parameters. The boundaries of the presynaptic bouton at rest
(before any stimulation) were calculated from the F values at rest and
included pixels with F values larger than the ROI mean plus 3 SDs (Fig.
1D, area outlined in blue). The area of suprathreshold pixels at rest was
approximated as a circle, and the resulting virtual “Bouton diameter” was
used as indicator of bouton size. The term “Peak amplitude” refers to the
peak F/F value of an averaged intensity transient derived from all su-
prathreshold pixels (Fig. 1E, distance between dotted red lines). Tau
decay (TauD) is the time constant of decay derived by fitting a monoex-
ponential function to the decay from the peak of the averaged transients
(Fig. 1E, amplitude between dotted red lines). The spatial extension of
the iGluu signal is described on the basis of a virtual diameter derived
from the area of all suprathreshold pixels combined to form a virtual
circle. The respective diameter is referred to as “Spread.” The term “Peak
spread” refers to the peak value of the averaged spread transient (Fig. 1F,
difference between dotted red lines). The indicator “Residual F/F” is
derived from fitting a double exponential function to the iGluu transient
after the last stimulus. It corresponds to the F/F value at the intercept
between the fast and slow phases of iGluu decay (Fig. 2E, red horizontal
line). “Integral F/F” refers to the sum of all responses during a series of
six stimuli at 100 Hz within a period of 70 ms starting with the first
stimulus. Dysfunctional synapses could best be detected by analysis of
single-pixel iGluu using the pixel with the highest iGluu elevation at any
given terminal. The highest iGluu elevations were always found within or
next to the bouton at rest. The peak amplitude of the single pixel transient
with the highest iGluu elevation will be referred to as “Maximal ampli-
tude” (see Fig. 4A–C, difference between red dotted lines). The respective
TauD values are referred to as “TauDmax.” In the following text, these
parameter names will be written in italics and capitals to underline that
these are predefined indicators introduced for the convenience of the
present single-synapse analysis.
Single-axon/bouton activation.To induce the Glu release from individ-
ual synaptic boutons under physiological conditions, a depolarizing cur-
rent pulsewas applied through anACSF-filled glass pipette (tip diameter,
1 M; resistance, 10 M	) placed next to an axon in close proximity
with a fluorescent varicosity. Responses were elicited at minimal inten-
sity at a repetition frequency of 0.1 Hz. They disappeared when the pi-
pette was moved by as little as 1m. Single-bouton recording of iGluu in
the presence of TTX was performed in elevated (5 mM) extracellular
[Ca2
] using a biphasic stimulation. For more details on single bouton
activation and the recording of unitary EPSCs (uEPSCs), see Kirischuk et
al., 1999, 2002; Dvorzhak et al., 2013a.
Patch-clamp recording of unitary EPSCs. uEPSCs were recorded in the
presence of bicucullinemethiodide, as previously described (Dvorzhak et
al., 2013b). Briefly, the intrapipette solution contained the following (in
mM): cesium methane sulfonate 100, CsCl 50, NaCl 5, CaCl2 0.5, EGTA
2.5, HEPES 25, MgATP 2, and GTP 0.3, at pH 7.2. uEPSCs were induced
via optical activation of action potentials (APs) in hChR2(E123T/
T159C)-EYFP-expressing corticostriatal axons. Using the point illumi-
nation system UGA-42 (Rapp OptoElectronic), the duration and size of
the laser pulse was adjusted to activate a synaptic response with distinct
threshold. Stimulation was accepted as minimal if the following criteria
were satisfied: (1) uEPSC latency remained stable (fluctuations20% of
means, (2) lowering stimulus duration by 20% resulted in a complete
failure of uEPSCs, and (3) an increase in stimulus duration by 20%
changed neither the mean amplitude nor the shape of uEPSCs. To elicit
AMPAR- and NMDAR-mediated components of uEPSCs, records were
performed at holding potentials of70 and
50 mV, respectively.
Synaptic EAAT2 immunofluorescence. Using deep isoflurane anesthe-
sia, mice were transcardially perfused with ice-cold PBS followed by a
solution of 4% (w/v) paraformaldehyde in PBS. Sagittal sections (30m)
were prepared as previously described (Rothe et al., 2015). Freely floating
sections were double stained with guinea pig anti-vGluT1 (1:1000) and
rabbit anti EAAT2 (1:2000), followed by respective secondary antibodies
at a concentration of 1:800. Grayscale 16 bit images (1091 1091 pixels;
pixel size, 0.073m; no binning) were acquired from the dorsal striatum
Figure 1. Monitoring single-synapse Glu transients in acute slices from adult mice after
expression of the genetically encoded ultrafast Glu sensor iGluu in corticostriatal neurons. A,
Resting iGluu fluorescence merged to the respective 63 differential interference contrast
image of a corticostriatal slice showing an axon with three adjacent varicosities and a stimula-
tion pipette at the central bouton.B, Simplified scheme of the corticostriatal circuitry (Reiner et
al., 2010), illustrating the concept of the preferential projection of PT neurons to indirect path-
way SPNs (iSPNs) and IT neurons to direct pathway SPNs (dSPNs),with size differences between
the IT and PT terminals. C, Bimodal distribution of bouton diameters as determined by the
suprathreshold resting fluorescence before stimulation. Boutons with diameter0.63m were
defined as “Large” and assumed to be issued by PT axons.D, Example of a PT-type boutonwith the
respective iGluu fluorescenceat rest (left) andat thepeakofanAP-mediated iGluu response (right).E,
F, iGluu responses recorded from the bouton shown inA andD. Experiment in 2mMCa
2
 and 1mM
Mg2
. E, Simultaneous recording of stimulation current (top trace) andmean intensity of suprath-
reshold pixels (bottom trace). Peak amplitude (between dotted red horizontal lines) and amonoex-
ponential function fitted to the decay from this peak (red overlay). TauD values are next to the fitting
curves.F, Plot of spreadagainst time (for adefinition, seeMaterials andMethods). Peak spread is the
differencebetweendottedredhorizontal lines.G,PositivecorrelationbetweenpeakspreadandTauD
afterstimulus#1.H,Peakamplitudeof responsestostimulus#1.There isnodifferencebetweensmall
and large terminals. I, Significant correlation between the PPR of peak amplitude and bouton diam-
eter. *p 0.05, **p 0.01, ***p 0.001.
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using a Zeiss 100 oil-immersion objective (NA, 1.3) and a Spot Insight
camera system (Diagnostic Instruments). All images were taken from the
dorsal striatum.Areas of interest (AOIs; 400 400 pixels; 853m2)were
cropped from the larger viewfields, selecting neuropil areas with a mini-
mum of cell somata or vessels. Quantification of EAAT2 immunofluo-
rescence (IF) was performed using ImagePro Plus (MediaCybernetics).
Within the selected AOIs, smaller ROIs (25 25 pixels; 3.33 m2) were
then centered to individual vGluT1
 spots to determine the level of
synaptic EAAT2 IF. A threshold algorithmwas used to define the bound-
aries of the EAAT2
 area, excluding pixels with F ROI mean plus 1.5
SDs. The data are expressed as integral intensity of suprathreshold pixels.
The term “Synaptic integral EAAT2 IF” refers to the mean value from 10
individually assessed ROIs (i.e., the environment of 10 vGluT1
 termi-
nals) within one AOI. The sections from three WTs and three Q175
HOMswere stained together, and all images were acquiredwith the same
camera settings. A total of 300 synapses were evaluated per genotype.
Statistics. Data analysis was performed with Prism 8 (GraphPad Soft-
ware). Considering that the comparison of the means could be influ-
enced by interanimal variance (Aarts et al., 2014), we have performed a
multilevel (“nested data”) analysis, where needed. p values of0.05 were
considered statistically significant. Significance levels were marked by
asterisks, as follows: *p 0.05, **p 0.01, and ***p 0.001. The abbre-
viation “ns” in the Figures means “not significant”. The numbers indicate
animals, cells, or presynaptic terminals, as mentioned in figure legends or
tables. Genotype-related effects are expressed as change in percentage of
meanWT values (Delta in Tables 2 and 4) or as effect strength according to
Cohen’s d or Hedges’ g. The d or g values0.8 suggest that the respective
effect was strong. The abbreviations DFn and DFd refer to the degrees of
freedom in the nested data analysis, as performed with GraphPad Prism.
DFn - degrees of freedom of numerator, DFd - degrees of freedom of
denominator.
Results
Evaluation of AP-mediated perisynaptic corticostriatal Glu
transients using the new ultrafast sensor iGluu in acute slices
from adult mice
Placement of stimulating electrodes in the vicinity of corticostria-
tal terminals at rest was performed under visual guidance (Fig.
1A). Bouton size was defined on the basis of resting fluorescence
Figure 2. Contrasting dynamics of Glu release from small and large corticostriatal terminals.A–D, Specimen records of AP-mediated iGluu signals from small and large boutons, as obtainedwith
20 and 100 Hz stimulation. All iGluu transients were elicited in an AP-dependent manner in 2 mM Ca
2
. Experimental conditions as in Figure 1. The large terminals produced a significant build-up
of residual iGluu (single arrow). The respective fluorescence added to the fast stimulus-locked transients after #6 (double arrow)]. E–I, Quantification of results.H, Note that the time integral of all
suprathreshold pixel intensities generated by a six-pulse train at 100 Hz during a sampling period of 70mswasmuch bigger in large boutons. Three-way ANOVA statistics: E: Levene’s test, F(df1
29, df2 29) 3.802, p 0.001; Small vs Large, F(1,29) 19.507, p 0.001; Frequency, F(1,29) 7.207, p 0.012; Animal, F(9,29) 0.765, p 0.649; Animal-Frequency, F(8,29) 1.154,
p 0.359; Animal-Small/Large, F(5,29) 0.46, p 0.803; Small/Large-Frequency, F(1,29) 0.000, p 0.999; F: Levene’s test, F(df1 29, df2 29) 2.202, p 0.020; Small vs Large,
F(1,29) 1.207, p 0.281; Frequency, F(1,29) 1.038, p 0.317; Animal, F(9,29) 4.330, p 0.002; Animal-Frequency, F(8,29) 2.398, p 0.041; Animal-Small/Large, F(5,29) 2.206, p
0.82; Small/Large-Frequency, F(1,29) 0.305, p 0.585; G: Levene’s test, F(df1 29, df2 29) 3.202, p 0.015; Small vs Large, F(1,29) 11.226, p 0.002; Frequency, F(1,29) 21.526,
p0.001; Animal, F(9,29)0.840,p0.575; Animal-Frequency, F(8,29)0.895,p0.533; Animal-Small/Large, F(5,29)0.818,p0.547; Small/Large-Frequency, F(1,29)0.155,p0.696;
H: Nested t test, F(1,12) 6.05, p 0.032; I: Nested t test, F(1,25) 6.47, p 0.018; Hedges’ g values: E: Small vs Large at 20 Hz, D 2.4; Small vs Large at 100 Hz, D 1.3; F: G 0.4 in all pairs;
G: Small vs Large at 20 Hz, D 1.4; Small vs Large at 100 Hz, D 1.1; H: D 0.8; I: G 1.0;H: G 1.0. The asterisks on the horizontal bars on the graphs denote significance levels according to
the nested t test. *p 0.05, **p 0.01, ***p 0.001.
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in the ROI (Fig. 1, thick blue outline). The deduced virtual Bou-
ton diameter exhibited a bimodal distribution (Fig. 1C). Varicos-
ities with a diameter0.57 mwere defined as “Small” and, for
the sake of brevity, tentatively referred to as IT type. Accordingly,
varicosities with d  0.63 m were classified as “Large” or PT
type. The size difference between terminals classified as Small
(IT) versus Large (PT) was significant at p 0.001 (Table 1).
After electrical stimulation of a fluorescent corticostriatal
axon in the dorsal striatum, iGluu intensity increased in the pixels
adjacent to the bouton at rest (Fig. 1D, thin black outline: active
area). To assess the dynamic characteristics of the iGluu signal,
the mean values of all suprathreshold pixel intensities (F/F)
generated by one synapse were plotted against time (Fig. 1E). The
Peak amplitude was determined, and a monoexponential func-
tion (Fig. 1E, red line) was fitted to the averaged iGluu transient
F/F to determine TauD. In the case of single-pulse activation,
there was no significant correlation between TauD and Bouton
diameter (not illustrated).
The focus of the current experiments was placed on the time
course of the iGluu signals. The position of the sensor and its low
affinity for Glu naturally set limits to the detection of [Glu] ele-
vations at larger distance from the site of vesicle exocytosis. Nev-
ertheless, we also expected some preliminary information on the
spatial characteristics of the iGluu signal. Therefore, the parame-
ter Peak spread was deduced from the projection of the suprath-
reshold iGluu area to the focal plane and plotted against time (Fig.
1F, distance between dotted red lines). Under the condition of
single-pulse activation, Peak spread exhibited a significant positive
correlation with TauD (Fig. 1G), but there were no terminal type-
related differences in themean values of Peak amplitude,TauD, and
Peak spread after single-pulse activation (Fig. 1H, Table 1).
The contrasting properties of IT- and PT-type terminals be-
came more obvious with repeated stimulation. Activation with
stimulus pairs at an interval of 50 ms revealed differences in the
paired pulse ratio (PPR) of Peak amplitude, resulting in a positive
correlation between PPR and Bouton diameter (Fig. 1I). This
finding validated our size criterion for synapse identification and
provided a first hint that IT and PT afferents may generate a
differential load for Glu clearance when repeatedly activated.
Frequency-dependent potentiation of Glu release at PT but
not IT corticostriatal terminals
As we aimed at exploring the limits of Glu release under condi-
tions resembling the cortical activity during movement initia-
tion, we applied two or six stimuli at frequencies of 20 or 100 Hz
to elicit AP-mediated Glu release. At all frequencies tested,
Small/IT and Large/PT terminals exhibited contrasting types of
short-term plasticity (i.e., depression or no change in IT and
potentiation in PT terminals; Fig. 2A–D, Table 1). The Peak am-
plitude observed after the last stimulus in a train normalized to
response #1 were larger in PT than in IT terminals (Fig. 2E, Table
1). The normalized TauD values exhibited little difference (Fig.
2F), but the normalized Peak spread values differed, being larger
at PT-type varicosities (Fig. 2G). When tested at 100 Hz, PT
synapses produced larger Integral F/F #1–6 than IT terminals
(Fig. 2H) and accumulated more Residual F/F (Fig. 2I). The
data suggest that the stimulus-locked response to the last AP adds
to already incompletely cleared synaptic Glu. Thus, under repet-
itive activation conditions, corticostriatal afferents might be af-
fected by conditions of weak astrocytic Glu uptake.
Directly induced Glu transients in tetrodotoxin
With the APmechanism intact, fluorescencemight also originate
fromneighboring release sites, especially if the axon heads deeper
into the z-plane of the slice. In the case of serial (en passant) type
synapses (as characteristic of PT afferents), this could errone-
ously increase signal duration and spread. Another caveat to be
faced in the case of HD preparations is a possible alteration of
voltage-activated channels in the cortical afferents (Silva et al.,
2017), which may affect the duration of the presynaptic depolar-
ization, the influx of Ca2
, and, consequently, the amplitude and
duration of iGluu signals, without having a direct impact on the
clearance machinery of the astrocytes. Moreover, respective def-
icits might preferentially occur in IT or PT axons. Considering
these complexities, it was decided to bypass theAPmechanismby
directly depolarizing the glutamatergic terminals in TTX and to
focus, initially, on just one type of terminal. We selected the
Large/PT input.
To achieve, under condition of TTX, at PT terminals [Glu]
elevations similar to those obtained under physiological activa-
tion conditions at 100Hz, it was sufficient to increase [Ca2
]ec to
5 mM and to add a hyperpolarizing prepulse to the standard 1 ms
depolarization used in both AP and TTX experiments. In the
absence of a conditioning hyperpolarizing prepulse, the direct
depolarization was insufficient to elicit release (Fig. 3A). The re-
sults shown in Figure 3, B and C, indicate that the selected pro-
tocol provided a goodmatch between the physiologically induced
#6 responses at 100 Hz and the directly induced responses in
TTX. In any case, iGluu elevations were completely abolished by
the Ca2
 channel blocker Cd2
 (Fig. 3D). This stimulation pro-
tocol was then expected to provide a reasonably standardized
challenge of the synaptic Glu uptake in WT or HD mice. In the
Table 1. Comparison of iGluu signals in varicosity types Small (presumably IT) and Large (presumably PT)
Varicosities type Small Varicosities type Large Statistics (nested t test)
iGluu signals at IT vs PT terminals Mean SE N-t N-a Mean SE N-t N-a F (DFn,Dfd) p Hedge’s g
Bouton diameter (m) 0.51 0.01 12 6 0.74 0.02 20 3 77.00 (1,14) <0.001 4.018
Peak amplitude #1 (%) 22.72 3.22 12 6 35.97 6.02 20 10 2.30 (1,14) 0.152 0.590
TauD #1 (ms) 4.65 0.75 12 6 4.56 0.39 20 10 0.01 (1,30) 0.906 0.044
Peak spread #1 (m) 1.54 0.19 12 6 1.24 0.11 20 10 1.76 (1,14) 0.206 0.518
First/last ratio peak amplitude, 20 Hz 0.68 0.06 12 6 1.18 0.05 20 10 37.50 (1,14) <0.001 2.382
First/last ratio peak amplitude, 100 Hz 0.98 0.09 10 6 1.61 0.14 17 9 10.1 (1,25) 0.004 1.269
First/last ratio peak spread, 20 Hz 0.74 0.04 12 6 1.02 0.05 20 10 11.9 (1,14) 0.004 1.367
First/last ratio peak spread, 100 Hz 1.13 0.1 10 6 1.5 0.08 17 9 7.58 (1,25) 0.011 1.097
IntegralF/F #1–6, 100 Hz 0.89 0.14 10 6 2.28 0.51 17 9 6.05 (1,12) 0.032 0.828
ResidualF/F amp after #6/peak amp #1, 100 Hz normalized 0.38 0.1 10 6 0.77 0.1 17 9 6.47 (1,25) 0.018 1.013
ResidualF/F spread after #6, 100 Hz (m) after 1.05 0.15 10 6 1.66 0.15 17 9 5.21 (1,12) 0.042 1.071
N-t, Number of terminals. N-a, number of animals;(%), difference to WT in % of WT (100%). See Materials and Methods for more details. Bold type indicates significant afferent-related difference according to multilevel analysis
(terminals nested in animals).
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following experiments (Figs. 4, 5), all synapseswere tested in TTX
applying paired (t  50 ms) biphasic pulses with a repetition
frequency of 0.1 Hz.
Slowed Glu clearance at single PT-type corticostriatal
terminals in HD mice
In the Q175mousemodel of HD,motor symptoms (hypokinesia
and dyskinesia, pathological circling) develop quite slowly. How-
ever, at 1 year of age, both Q175 heterozygotes (HETs) and
HOMs resemble the human phenotype at a symptomatic stage
(Khakh et al., 2017). In Q175 HOMs, motor impairment coin-
cided with the appearance of pathological gamma oscillations in
the local field potential (LFP) recordings at quiet rest (Rothe et
al., 2015). In R6/2 mice, the changes in the LFP power spectrum
were less pronounced after treatment with CEF, a transcriptional
activator reported to increase the level of EAAT2 protein in the
dorsal striatum (Miller et al., 2012). TFB-TBOA is a blocker of
Glu uptake (Shimamoto et al., 2004). Its applicationwould there-
fore simulate the effect of reduced EAAT2 expression/activity in
HD mice. Figure 4A–C shows representative single-synapse re-
cords from WTs, HETs, and HOMs. The black traces in Figure
4A–C are individual pixel transients; the values between the dot-
ted lines correspond to theMaximal amplitude. The white line is
the mean transients derived from all suprathreshold pixels of a
synapse. The monoexponential fitting curves are shown in gray
(WTs), red (HETs), or magenta (HOMs). Figure 4D presents the
amplitude-scaled average responses for the three genotypes illus-
trating our main finding, as follows: in HD slices, the iGluu tran-
sients decay more slowly than in WT mice (also see Movie 1).
Interestingly, this HD-related alteration was significant not only
in Q175 HOMs but also in HETs (Fig. 4E), thereby demonstrat-
ing the usefulness of the Q175 HETmodel for research on astro-
cyte pathology in HD mice.
An important additional question concerns the amount of
released Glu. Is it increased by HD? This was not the case, on the
contrary. Despite a considerable variability in thePeak amplitude,
we found a tendency for smaller amplitudes in HD (Fig. 4F, Ta-
bles 2, 3). Unfortunately, multilevel data analysis failed to verify
the difference between WTs and HD due to the small number of
availableHOMs.Our result is, however, in linewith the data from
R6/2 (Parievsky et al., 2017), suggesting that the presently dis-
closedHD-related prolongation of the iGluu signal occurs despite
a concomitant decrease in the Glu output from single PT
terminals.
The above observations do not immediately prove that the
prolongation of the iGluu transients in HD mice were due to
altered functionality of the astrocytes. It was at least necessary to
clarify whether TauD responded to pharmacological manipula-
tion of astrocytic Glu transport. This was the case. The iGluu
transients of PT terminals exhibited a clear sensitivity to TFB-
TBOA (Fig. 4G). InWTs, 100 nM antagonist prolonged the iGluu
decay to the same extent as the disease (Fig. 4I), with the effect of
pharmacological EAAT2 block being less pronounced in Q175
HOMs (Fig. 4H, I).
According to the presently available models of glutamatergic
synapses (Zheng et al., 2008; Scimemi and Beato, 2009), a spread
of 1.25 m should be sufficient to activate extrasynaptic
NMDA receptors. Although iGluu expression in the presynaptic
terminals cannot provide exhaustive information on the spatial
characteristics of perisynaptic [Glu], we nevertheless examined
the Peak spread (Fig. 4J, black outlines). There was a tendency for
increase (Fig. 4K), but this tendency failed to reach significance in
nested ANOVA (Fig. 4L) and nested t tests (Tables 2, 3). The
mean spread velocity (1.5m/s) did not varywith the genotype
(Fig. 4M).
Positive correlation between Glu release and clearance in HD
but notWT synapses
Cumulative histograms and correlograms were plotted for fur-
ther analysis of HD-related synapse pathology. The graphs of
Figure 5, except for panels D and E, are based on the values
obtained from 35 WT and 32 HET synapses, as explained by the
evaluation scheme in Figure 5A. Each synapse is represented with
three consecutive trials elicited at a frequency of 1/10 Hz. The
interval between the stimuli for #1 and #2 was 50 ms. All data are
from experiments in TTX. Figure 5, B and C, shows the relative
probability of occurrence of Peak amplitude and TauD, based on
a total of 105 #1 responses from 35 WT synapses and 96 #1 re-
sponses from 32 HD synapses.
Due to the highly variable configuration of the individual syn-
apses with respect to the surrounding tissue and the focal plane of
the camera, and due to interanimal variation, the values obtained
from the averaged iGluu trials of different synapses exhibited con-
siderable variability. It was therefore necessary to normalize the
data. Among several possibilities, we chose the #1 response of
every trial to normalize the #2 responses. Typically #2 responses
were smaller after larger #1 responses, and vice versa (Fig. 5A).
The normalization reduced the impact of intersynapse variability
in favor of intertrial variability. If in a given trial glutamate output
touched the limits of uptake, one could expect that such a release
event would produce a prolonged [Glu] transient. In contrast, if
uptake capacity were sufficient for any amount of released gluta-
mate, the fluctuating TauD values should be independent on
Peak amplitude. It can be seen (Fig. 5D,E) that HD but not WT
synapses displayed a positive correlation betweenTauD and Peak
amplitude, consistent with the proposal that in HD mice some
Figure 3. Responses to directly induced test pulses bypassing the AP mechanism in WT
boutons of typePT.A, Experiment in elevated [Ca 2
]ec. Left, Response to electrical stimulation
in the absence of TTX elicited by a short (1 ms) depolarizing pulse. In 5 mM Ca 2
, the AP-
mediated response exhibits paired pulse depression. Middle, Same condition but in the pres-
ence of TTX. Note the complete block of Glu release. Right, Response in 5mM Ca 2
 and TTX, but
elicited with the 1 ms depolarizing pulse preceded by a short hyperpolarizing pulse. This con-
figuration will in the following be referred to as “Ca5-Dir”. B, C, Stimulus intensity for direct
activationofGlu release in TTX (“Ca5 -Dir”)was adjusted such that thepeak amplitude andpeak
spread of iGluu signals matched the amplitudes observed with the last (#6) 100 Hz response
under physiological conditions (“Ca 2 - AP”).D, The directly induced responseswere completely
blocked by Cd 2
 (500M). Cohen’s d: CTRL vs Cd 4.4, Cd vsWash 2, CTRL vsWash 2.3.
*p 0.05, **p 0.01, ***p 0.001.
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synapses exhibited signs of clearance in-
sufficiency, with the prolongation of
TauD being more pronounced in trials
with enhanced Peak amplitude.
Identification of
dysfunctional synapses
The pixels with the highest stimulus-
induced elevations of F/F were always
located within or immediately next to the
boundaries of the resting terminal (Fig.
1D). The Maximal amplitude derived
from the highest single pixel transient can
be regarded as a measure of the Glu out-
put, while TauDmax would reflect the
clearance at the site of release, minimizing
the influence of Glu diffusion. Figure 5, F
and G, presents the cumulative probabili-
ties of the occurrence of Maximal ampli-
tude andTauDmax. One can see that none
of the HET entries of Maximal amplitude
were350%, and24%ofTauDmax en-
tries exceeded 15 ms. Forty percent of the
tested synapses generated TauDmax 15
ms in at least one of the three trials, and all
of these responses were 350%. The dif-
ferences in the ranges of these two indica-
tors of release and clearance, respectively,
are even more obvious in the correlo-
grams of Figure 5,H and I. TauDmax val-
ues 10 ms were (with one exception)
absent in WT synapses tested with direct
depolarization. As a first approximation,
one can therefore state that, according to
the distribution of TauDmax in WTs and
Q175 HETs aged 15–19 months, 40% of
HET synapses in the dorsal striatum ex-
hibited a pathological phenotype. Of
course, this estimation is nomore than an
educated guess based on the assumptions
that 15ms is the largestTauDmax value to
be expected in WTs, and that in WTs all
synapses are fully functional. The data
also hint that in dysfunctional synapses
Glu may find its astrocytic transporter at
greater distance, which is in line with re-
cent FRET data from corticostriatal syn-
apses in R6/2 (Octeau et al., 2018).
Figure 4. HD-related differences in the clearance of synaptically released Glu. A–C, Superposition of suprathreshold pixel
transients induced by direct activation of PT-type varicosities in the presence of TTX. Differences between dotted red horizontal
lines: Maximal amplitude of a single pixel transient. In white: averaged transient from all suprathreshold pixels. Curves in gray
(WT), red (HET), andmagenta (HOM), monoexponential function fitted to the decay from peak amplitude.D, Averaged responses
normalized to samepeak amplitude; sameboutons as inA–C. The respective fitting curves highlight thedifferences in theduration
4
of the Glu transients. E, F, Quantification of results from the
entire dataset. WTs, Gray; HETs, red; HOMs, magenta. G, Incu-
bation of WT slices in 100 nM TFB-TBOA simulated the depres-
sion of Glu clearance observed in HOMs. H–L, Specimen
images, traces, and quantification for the spread inWT andHD
mice.M, Lack of genotype-related differences in spread veloc-
ity. Nested ANOVA statistics: E: F(2,26) 4.17, p 0.027; F:
F(2,26) 2.7, p 0.086; I: F(3,15) 5.5, p 0.0095; L: F(2,26)
 0.52, p 0.600;M: F(2,26) 0.65, p 0.528. *p 0.05,
**p 0.01, ***p 0.001. See Table 2 for more details.
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Reduced perisynaptic EAAT2 protein at
corticostriatal terminals
To clarifywhether the observed clearance deficit is indeed accom-
panied by a reduction of EAAT2 protein levels in the environ-
ment of corticostriatal terminals, we performed a quantification
of EAAT2 IF in fixed sections, as described in Materials and
Methods and illustrated in Figure 6A–M.
It has frequently been observed, and could possibly be noticed
in the examples of Figure 6A–D, that in 100 images from the
dorsal striatum of HD mice the areas preferentially occupied by
neuropil (i.e., areas without “holes” from the somata of neurons
and astrocytes) are smaller than in WT mice. Moreover, a vari-
able fraction of vGluT1
 varicosities seemed to be devoid of
synaptic EAAT2
 clusters, notably in HD mice (Fig. 6D, red
boxes). Finally, due to the presence of capillaries and the attached
astrocyte end-feet, there were EAAT2
 clusters without
vGluT1
 counterparts (Fig. 6B, arrows). To avoid ambiguity
resulting from these complexities, it was decided to quantify syn-
aptic EAAT2 IF individually in sufficiently small ROIs (1.825 
1.825m2) centered to just one vGluT1
 terminal. Figure 6E–L
shows representative ROIs selected from larger AOIs in the dorsal
striatum (Fig. 6, B,D, white boxes). A threshold algorithm was
used to delineate the boundaries of the EAAT2 clusters from
where the Synaptic integral EAAT2 IF values were actually sam-
Figure 5. Relationship between Glu release and uptake, and the identification of dysfunctional synapses in HD. A, Basal scheme of data organization. B–I, The graphs are based on
three consecutive trials from each synapse. Data are from 35 PT-typeWT synapses and 32 HET synapses, except for D and E. B, C, Cumulative histograms of #1 Peak amplitude and #1 TauD
values. D, E, Plots of normalized (to # of the first trial) #2 responses. Data from 31 PT-type WT synapses and 30 HET synapses. Note that HETs but not WTs exhibited a positive correlation
between TauD and Peak amplitude. In E, the slope parameters of the three predictors Peak amplitude, Trial, and Animal were significant for Peak amplitude ( p 0.015) and Animal ( p
0.002). The latter suggests that in different Q175 HETs the disease has progressed to different degrees. Significance levels for other variables: Peak amp*Animal - p 0.003, Peak
amp*Trial - n.s., Trial*Animal - n.s. F, G, Cumulative histograms of #1 Maximal amplitude and #1 TauDmax. In the HET sample, all Maximal amplitude values were350%. In the WT
sample, all TauDmax values were15 ms. A total of 40 synapses exhibited in at least one of the three trials a TauDmax value exceeding the Threshold defined by the longest TauDmax
value in WTs. Twenty-four percent of the HET trials exceeded the 15 ms limit. Accordingly, 30% of the WT responses were larger than in HETs, and these suprathreshold responses were
derived from 51% of the synapses. H, I, Correlograms of TauDmax and Maximal amplitude for WT and Q175 HET. These graphs emphasize the HD-related differences in the ranges of
Maximal amplitude and TauDmax. Maximal amplitude values exclusively seen inWTs are shown in gray, and TauDmax values exclusively encountered in HETs are shown in red. *p 0.05,
**p 0.01, ***p 0.001.
Movie 1. Slow motion video, factor 1240. Top row, Images from
WT (left), Q175 HET (middle), and HOM (right). Bottom row, Respective
averaged iGluu transients from all suprathreshold pixels.
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pled. Each data point in Figure 6N represents the mean value
from10ROIs of 1 AOI. vGluT1
 terminals without any suprath-
reshold EAAT2 were avoided, which may have caused an underes-
timation of the actual difference. Nested data analysis showed that
the synaptic integral EAAT2 IF was significantly lower in HD mice
(Fig. 6N, Tables 2, 3). TheCohen’sd value (0.7878) suggests a strong
HD-related effect (26%). The histogram of synaptic integral
EAAT2 intensity (Fig. 6O) illustrates the overall shift toward lower
values of Synaptic integral EAAT2 IF in individual ROIs.
Prolonged NMDAR components of unitary EPSCs in HD
NMDARs are sensitive indicators of [Glu] and therefore well
suited to detect a potentially existing Glu clearance deficit in the
environment of active synapses, provided that the analyzed re-
sponses are derived from one or few synapses only (Chiu and
Jahr, 2017). CEF is known to stimulate the transcription of
SLC1A2 (i.e., the gene encoding EAAT2). It is therefore used to
verify a contribution of EAAT2 in a pathology or recovery effect.
Functional benefits from CEF injections have already been re-
ported (Miller et al., 2008, 2012) andwere attributed to enhanced
EAAT2 expression in astroglia. Here we used focal optical stim-
ulation of individual channel rhodopsin-expressing corticostria-
tal axons to record uEPSCs at 70 and 
50 mV. The
experiments showed that the T50 value of the uEPSC recorded at

50 mV is (1) solely dependent on NMDARs; (2) prolonged in
HD mice; and (3) recovered to WT levels after treatment with
CEF, suggesting a sensitivity of corticostriatal input to the level of
EAAT2 expression (Fig. 7A–C, Table 4). Other parameters of
corticostriatal uEPSCs were found unchanged by HD (Fig. 7D–
F). However, more work is needed to actually prove that the
observed potentiation of NMDAR activity in striatal projection
neurons (SPNs) had been a result of wider spread of synaptically
released glutamate.
Discussion
The analysis of single-synapse iGluu transients in acute slice prep-
arations from adultmice provides new information onGlu clear-
ance in its relation to the respective transmitter load. (1) After
single-pulse activation, IT and PT synapses coped with the in-
duced [Glu] elevations, but when challengedwith high activation
frequencies the [Glu] elevations produced by PT and IT termi-
nals differed significantly (factor 2.6:1 for Integral F/F at 100
Hz). (2) In HD mice, PT iGluu transients were found to decay
more slowly. About 40% of HD synapses (14 of 32 in HETs) can
be regarded as deficient, considering the time needed for com-
plete Glu clearance (TauD of iGluu  15 ms). (3) At any given
terminal, the responses exhibited some intertrial variability. The
analysis of normalized #2 responses from three trials at the same
synapse revealed that in Q175 HETs, but not WTs, iGluu tran-
sients with larger Peak amplitude were associated with larger
TauD, which is evidence for a disease-related loss of indepen-
dence between the indicators of uptake and release. (4) HD de-
creased the range ofMaximal amplitude but increased the range
of TauDmax. (5) Immunostaining suggests that the immediate
environment of corticostriatal terminals contains less EAAT2
protein. (6) The NMDAR-mediated unitary EPSCs elicited by
optical stimulation of single ChR-expressing corticostriatal ax-
ons were prolonged in Q175 HOMs.
PT versus IT terminals
The unexpected differences in the properties of PT versus IT termi-
nals raise further questionson themechanismsof releaseplasticity at
the glutamatergic afferents to the dorsal striatum. Previous electro-
physiological studies (Ding et al., 2008) implied that corticostriatal
connections preferentially exhibit paired pulse facilitation (PPF),
while thalamostriatal connections are prone to paired pulse depres-
sion (PPD). Our results confirm preferential PPF with regard to the
PT subgroup of corticostriatal afferents under physiological activa-
tion conditions (Table 1). However, as in any other synapse
(Kirischuk et al., 2002), a conversion from PPF to PPD is easily
achieved by increasing the Ca2
 influx. There is a widely accepted
rule of thumb suggesting that smaller initial responses are likely to
produce facilitation, andviceversa.Considering thatunder the same
experimental conditions PT and IT terminals produced about the
same initial Glu output but opposite types of frequency-dependent
plasticity, one can assume that these terminals indeed represent two
classes of afferents with some differences in the presynaptic control
of transmitter release.
Under condition of repetitive activation, the size of synaptic ter-
minals and associated differences in the vesicle pool size could affect
the integralGluoutput, andalso thedegreeofGluescape (Genoudet
al., 2006; Bernardinelli et al., 2014;Medvedev et al., 2014;Gavrilov et
al., 2018). It hasbeenhypothesized that thicker terminals couldpush
thePAPs fartheraway fromthesiteof exocytosis,whichmayresult in
wider signal spread if the transporters are challenged with a pro-
nounced buildupof [Glu], as found inPT terminals.
Table 2. Comparison of WTwith Q175 HET or HOM
WT HET HOM
Mean SE N-t N-a Mean SE N-t N-a (%) Mean SE N-t N-a (%)
Directly induced iGluu transients at PT terminals
Varicosity diameter (m) 0.77 0.01 35 10 0.76 0.015 32 16 n.s. 0.72 0.017 20 3 n.s.
Peak amplitude (%) 87.90 7.28 35 10 63.57 5.18 32 16 ns 45.07 6.22 20 3 ns
TauD (ms) 3.39 0.41 35 10 11.28 2.14 32 16 233 14.27 3.60 20 3 321
Peak spread (m) 1.28 0.06 35 10 1.55 0.09 32 16 n.s. 1.59 0.13 20 3 n.s.
Synaptic EAAT2 IF at vGluT2 terminals
Synaptic integral EAAT2 IF (a.u.) 356.3 25.12 30* 3 263.1 17.5 30* 3 26
See Materials and Methods section for more details. N-t, number of terminals; N-a , number of animals;(%), difference to WT in % of WT (100%). Bold type indicates significant genotype-related difference according to multilevel
analysis (level 1, animals; level 2, terminals).
*Each data point represents the mean value from 10 synapses within one area of interest.
Table 3. Statistics for Table 2
WT-HET WT-HOM
Genotype effect
(nested t test) F (DFn,Dfd) p Hedges’ g F (DFn,Dfd) p Hedges’ g
Varicosity diameter (m) 0.005 (1, 24) 0.943 0.046 1.542 (1, 11) 0.240 0.046
Peak amplitude (%) 1.050 (1, 24) 0.317 0.655 2.220 (1,11) 0.165 1.118
TauD (ms) 5.690 (1, 24) 0.025 0.922 9.151 (1, 11) 0.012 1.105
Peak spread (m) 1.489 (1, 24) 0.234 0.618 0.2539 (1, 11) 0.624 0.665
Synaptic integral
EAAT2 IF (a.u.)
9.403 (1, 58) 0.003 0.788
See Materials and Methods for more details.
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The hypothesis of nonsaturating Glu uptake in healthy
glutamatergic synapses
In view of a long history of changing opinions on the significance
of astrocytic Glu transport as a possible determinant of synaptic
strength, it is good to have new tools at hand to shed light on the
possible limits of Glu clearance in health and disease. Our uEPSC
data from synaptic connections with one or few terminals confirm
the long-standing idea that a weakness of Glu uptake has little influ-
ence on the decay kinetics of the fast-desensitizing AMPA responses
(Hestrin et al., 1990;Asztely et al., 1997;Goubard et al., 2011;Camp-
bell et al., 2014). Moreover, our iGluu data from healthymice are in
line with the more controversial prediction that in “normal” gluta-
matergic synapses glutamate transportwould copewith anyamount
of physiologically released Glu (Diamond and Jahr, 2000; Tzingou-
nis andWadiche, 2007). Nevertheless, the present iGluu-based pos-
tulate of nonsaturating Glu uptake for IT- and PT-type
corticostriatal synapses will need further verification under a wider
range of conditions. It was already shown that the state of astrocytes
could affect the structural plasticity of PAPs (Theodosis et al., 2008;
Reichenbach et al., 2010; Bernardinelli et al., 2014; Heller and Rusa-
kov, 2015; Verkhratsky and Nedergaard, 2018). Activity- and
disease-dependent PAP retraction could produce a large variety of
spill-out and spill-in effects,whichmaynotonly change the access of
the available transmitters to respective neuronal and glial receptors,
but also influence the efficacy of the astrocytic transport machinery
itself (Armbruster et al., 2016).
Evidence for impairment of Glu clearance in HD
Symptomatic HD is characterized by the loss of glutamatergic
terminals in the dorsal striatum, but it is still not clear whether
this disease-related process of synapse pruning is to be attributed
to glutamate excitotoxicity (Reiner and Deng, 2018). While the
Figure 6. HD-related reduction of synaptic EAAT2 IF. Data from three male Q175 HOMs (CAG range, 176 –191; age range, 49 –54 weeks) and three male WT siblings. A, C, AOIs cropped
from larger view fields for quantification of synaptic integral EAAT2 IF. Numbers on EAAT2 image: mean AOI IF intensity (no intensity threshold, same display range for WTs and HOMs).
B, D, Overlay of vGluT1 and EAAT2 images (display ranges optimized for object recognition). Squares outlined in white show ROIs as used for the estimation of synaptic integral EAAT2
IF. Both WT and HOM images contain numerous EAAT2 clusters without synaptic terminals, presumably representing astrocytic end-feet in contact with blood vessels (see arrows in B).
In HD, vGluT1 varicosities may occur without EAAT2 clusters (ROIs boxed in red). E–L, Enlarged ROIs showing (in this order) vGluT1, EAAT2, overlay, and the suprathreshold EAAT2, as used
for the estimation of integral EAAT2 IF in the immediate vicinity of one corticostriatal vGluT
 terminal. Numbers on ROIs indicate integral suprathreshold fluorescence intensity for the
EAAT2 channel. M, Histogram of AOI EAAT2 pixel intensity. Note that “holes” from somata and blood vessels would influence the mean AOI values of EAAT2 intensity. N, Small ROI
quantification of synaptic integral EAAT2 intensity by nested data analysis. Each data point represents the mean from 10 rectangular ROIs within 1 AOI. Dotted lines indicate the mean
level from three animals (with a total of 30 AOIs, 300 synapses) per genotype. Numbers on column: AOIs and animals (in brackets); same for all columns. Statistics (F, DFn, DFd): 9.403,
1, 58. p 0.0033. O, Histogram of synaptic integral EAAT2 fromWTs and Q175 HOMs. n 300/group. Effect size (Cohen’s d) was obtained with the t value calculated by the nested t test.
#, Animal number; a.u., arbitrary units; WT, light gray; HOM, magenta. *p 0.05, **p 0.01, ***p 0.001.
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long-term consequences of reduced Glu clearance remain to be
clarified, our present experiments provide new evidence, sug-
gesting that in symptomatic Q175 mice a significant fraction
of PT (40%) synapses is afflicted by the disease, most likely
exhibiting alterations in both uptake and release. When ana-
lyzing the normalized Peak amplitude in three consecutive
trials of the same synapse, it turned out that HD but not WT
synapses displayed a positive, presumably pathological corre-
lation between Peak amplitude and TauD. Considering in
addition that (1) treatment of WT synapses with TBOA pro-
duced TauD values similar to those in HD synapses, and (2)
Synaptic integral EAAT2 IF was significantly less in HD syn-
apses, it is suggested that glutamate uptake, in general, and
astrocytic EAAT2 deficiency, in particular, contribute to the
observed synaptic dysfunction in HD synapses.
However, this conclusion is not shared by all researchers. First
of all, there is some evidence that EAAT2 is also localized on
presynaptic terminals. In the R6/2 model of HD, the Rosenberg
group (Petr et al., 2013) confirmed the reduced expression of
EAAT2 and the beneficial effects of CEF. But experiments with
partial knockdown of SLC1A2 revealed little change in the frac-
tion of EAAT2
 terminals and, even more important, in the
progression ofHD. Based on these and other findings, Rosenberg
et al. questioned a role of EAAT2 in the pathogenesis of HD and
forwarded the intriguing hypothesis that the observed down-
regulation of EAAT2 applies to a nonfunctional intracellular frac-
tion of the EAAT2 protein. We find the reported 40% reduction
in the glutamate uptake activity in synaptosomes after condi-
tional GLT1 knockout (Petr et al., 2015) somewhat surprising,
comparing their results with the present material where no more
than 5% of the terminals exhibited full colocalization of vGluT1
and EAAT2 IF.
Considering the novelty of our present approach, it is not so
unexpected that some results from other laboratories were not
confirmed, in particular those obtained with the slow glutamate
sensing fluorescent reporter (iGluSNFR; Marvin et al., 2013).
Parsons et al. (2016) activated glutamate release by high-
frequency electrical field stimulation and used the iGluSnFR sen-
sor to record Glu elevations in large viewfields. They found no
HD-related difference in the fluorescence decay, in contrast to
the findings of Jiang et al. (2016). Both studies were performed in
R6/2 mice, the main difference being the site of expression of the
Glu sensor (neurons vs astrocytes). Parievsky et al. (2017) applied
optical field stimulation of channel-rhodopsin [ChR2(H134R)]-
expressing corticostriatal axons to induce EPSCs in SPNs. This
approach showed no increase in the decay times (T90-10) of
NMDAR-mediated currents. On the contrary, the latter were sig-
nificantly shorter in HD.However, considering themean T90-10
values of this study (750 ms), it seems possible that the asyn-
chrony of release produced by this type of optical field stimula-
tion may not give the resolution needed for the estimation of
synaptic Glu clearance. In general, time- and volume-averaging
effects resulting frombulk activation of synaptic and nonsynaptic
Glu release and low resolution of the electrical or fluorescent
signals can be expected to influence the interpretation of results
on Glu uptake and release (for review, see Jensen et al., 2017;
Reynolds et al., 2019).
A question receiving growing attention in the field of synaptic
plasticity and dysfunction is the role of other glutamate uptake
mechanisms. Bellini et al. (2018) illuminated the role of Glu up-
take from two sides: pathology and functional rescue. Their con-
vincing evidence suggests that the neuronal Glu transporter
EAAT3 (EAAC1) ensures long-term synaptic activity by reducing
the activation of mGluR1 in the striatum.
The ultimate proof of Glu uptake deficiency as a cause of
synapse pathology in the dorsal striatum will be the recovery of
normal synaptic performance after a therapeutic intervention
targeting the astrocytes. Most intriguing, intrastriatal injec-
tion of a recombinant viral Kir4.1 vector restored a normal
level of EAAT2 protein (Tong et al., 2014). However, it is not
yet clear whether a mere stimulation of EAAT2 expression
would suffice to achieve the desired reversal of motor symp-
toms in HD, because synaptic targeting and the activity of Glu
transporters are also influenced by local translation (Sakers et
al., 2017), lateral mobility (Murphy-Royal et al., 2015), and
internalization (Leinenweber et al., 2011; Iba´n˜ez et al., 2016).
Clearly, much more information is needed to understand the
regulation of Glu uptake in the context of other astrocytic
signaling cascades.
Figure 7. HD-related prolongation of the NMDAR component in uEPSCs elicited by optical
stimulation of single corticostriatal afferents visualized by EYFP fluorescence after the expres-
sion of CaMKIIa.hChR2(E123T/T159C)-EYFP.hGH. A, Specimen traces as recorded at two differ-
ent holdingpotentials in thepresenceof bicucullinemethiodide (25M).B, Same traces as inA,
but aligned topeak. Seeprolongeddecay in contrast to records at70mV. Thehalf-decay time
of the uEPSC (T50) was sensitive to APV (not illustrated). Treatment with CEF shortened the
uEPSC at
50mV toWT level (blue traces).C–F, Quantification of results. Note the significantly
larger T50 values of the NMDAR-mediated response at
50 mV and recovery after CEF treat-
ment (C). Numbers in columns: the number of tested SPNs and animals (in parentheses). For
detailed results of nested data analysis and Hedges’ g values, see Table 4. *p 0.05, **p
0.01, ***p 0.001.
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